Core Viewpoint - Illumina Inc. has seen a rise in its stock price following the announcement of reimbursement for its FDA-approved TruSight Oncology Comprehensive test, which is expected to enhance the adoption of genomic profiling in the U.S. healthcare system [1][2]. Group 1: Reimbursement and Test Impact - The reimbursement from the Centers for Medicare and Medicaid Services (CMS) will be at a rate of $2,989.55 per test, effective January 1 [2]. - The TruSight Oncology Comprehensive test assesses over 500 genes, promoting broader access to precision oncology diagnostics [3]. - Approximately 60% of Illumina's sequencing consumables revenue was attributed to clinical customers last year, indicating significant growth potential [3]. Group 2: Stock Performance and Analyst Insights - Illumina's stock is currently trading 2.65% above its 12-month moving average, with a 2.9% increase over the past year [4]. - The stock carries a Neutral Rating with an average price target of $130.24, and analysts expect a 28% earnings growth, justifying the premium P/E multiple [7]. - Recent analyst actions include a Hold rating from TD Cowen with a target raised to $140.00 and a Buy rating from Guggenheim with a target raised to $144.00 [8]. Group 3: Benzinga Edge Rankings - Illumina scores high on the Benzinga Edge rankings, with a Momentum score of 86.32/100 indicating strong short-term performance, but a low Value score of 18.92/100 suggesting it is trading at a steep premium [9][10]. - The EPS estimate is $1.22, up from $0.95 year-over-year, while the revenue estimate remains at $1.10 billion [8]. Group 4: ETF Impact - Illumina shares were up 2.52% at $145.22, with significant weights in various ETFs, including 3.84% in Invesco S&P MidCap Quality ETF and 4.39% in First Trust NYSE Arca Biotechnology Index Fund [11].